XELIRI

Phase 3Small molecule

ZZhejiang Cancer Hospital

XELIRI is one of 54 small molecule programs targeting Rectal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rectal AdenocarcinomaActive, not recruiting

Colorectal CancerActive, not recruiting

Rectal AdenocarcinomaPhase 3

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

XELIRI

ZZhejiang Cancer Hospital

Phase 3

1 2

Eylea

Regeneron

Preclinical

5 3

PORTRAZZA

Emend IV

Ketalar

AAultman Health Foundation

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Vascepa

AAmarin Pharma Inc.

Preclinical

1 9

Andriol

AAuxilium

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Colon Cancer1 trial

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00127036·65 enrolled

Clinical Trial1 trial

PRECISE CURATE.AI Pilot Clinical Trial

Unknown status·NNational University Hospital, Singapore·Phase 1/2·NCT04522284·20 enrolled

Colorectal Cancer1 trial

XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

Unknown status·HHarbin Medical University·Phase 2·NCT03511170·66 enrolled

Rectal Adenocarcinoma1 trial

A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT05669092·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for XELIRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XELIRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XELIRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZhejiang Cancer Hospital

XELIRI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Colon Cancer1 trial

Clinical Trial1 trial

Colorectal Cancer1 trial

Rectal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News